Allergan to Acquire Bonti, Adding New Neurotoxin Programs
Allergan, a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin…
FDA Rejects Allergan’s Ulipristal Acetate New Drug Application
Allergan has received a Complete Response Letter (CRL) from the FDA in response to the New Drug Application (NDA) for ulipristal acetate (UPA) for the treatment of abnormal uterine bleeding in women with uterine fibroids. The letter from the FDA indicates it is not able to approve the ulipristal acetate NDA in its current form and…
Allergan Files Suits Over Unlawful Manufacture and Sale of Unapproved New Drugs
Allergan and Saint Regis Mohawk Tribe Announce Agreements Regarding Restasis Patents
Allergan’s Pending Acquisition of Zeltiq Progresses Toward Completion
First FDA-Approved Preservative-Free Prescription Eye Drop Available in Multidose Bottle
Allergan announces availability of Restasis MultiDose (Cyclosporine Ophthalmic Emulsion) 0.05% — the first FDA-approved preservative free prescription eye drop available in a multidose bottle. Allergan plc announced the availability of Restasis MultiDose, which is the same preservative-free Restasis formulation, but now offered in a multidose bottle. Restasis is the first and only prescription medication FDA-approved to help…
